KalVista Pharmaceuticals (KALV) Net Income (2016 - 2025)
KalVista Pharmaceuticals' Net Income history spans 11 years, with the latest figure at $39.4 million for Q2 2025.
- On a quarterly basis, Net Income rose 34.35% to $39.4 million in Q2 2025 year-over-year; TTM through Apr 2025 was -$45.5 million, a 19.97% increase, with the full-year FY2025 number at -$91.8 million, down 74.34% from a year prior.
- Net Income hit $39.4 million in Q2 2025 for KalVista Pharmaceuticals, up from -$44.5 million in the prior quarter.
- Over the last five years, Net Income for KALV hit a ceiling of $39.4 million in Q2 2025 and a floor of -$44.5 million in Q4 2024.
- Historically, Net Income has averaged -$14.4 million across 4 years, with a median of -$28.6 million in 2023.
- Biggest five-year swings in Net Income: plummeted 53.45% in 2024 and later skyrocketed 34.35% in 2025.
- Tracing KALV's Net Income over 4 years: stood at -$12.5 million in 2021, then tumbled by 131.39% to -$29.0 million in 2023, then plummeted by 53.45% to -$44.5 million in 2024, then skyrocketed by 188.65% to $39.4 million in 2025.
- Business Quant data shows Net Income for KALV at $39.4 million in Q2 2025, -$44.5 million in Q4 2024, and -$40.4 million in Q3 2024.